Abstract
A phase II study was performed to assess the efficacy and toxicity of the combination of cisplatin (CDDP) and tamoxifen (TAM) in patients with metastatic malignant melanoma (MM). A total of 31 consecutive previously untreated patients with unresectable measurable MM were given 100 mg/m2 CDDP every 21 days and 60 mg TAM every 12 h daily. All courses were given on an outpatient basis. A total of 119 courses of treatment were given. In all, 5 of the 31 patients (16%) had an objective response (95% confidence interval 5.3 – 34%) and 2 (6%) achieved a clinical complete response. The median duration of response was 7 months. The main side effect was gastrointestinal: 13% of the patients experienced grade 3/4 nausea/vomiting. Hematological or neurological toxicities were mild and rare. In conclusion, the combination CDDP-TAM has limited activity in MM, although its toxicity is tolerable. Our results do not allow us to recommend its use for the treatment of MM.
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Additional information
Received: 27 August 1995 / Accepted: 15 November 1995
Rights and permissions
About this article
Cite this article
Feliu, J., Barón, M., Chacón, J. et al. Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen. Cancer Chemother Pharmacol 38, 191–194 (1996). https://doi.org/10.1007/s002800050469
Issue Date:
DOI: https://doi.org/10.1007/s002800050469